Author: Ravi Shankar

More than 200 ABM professionals help keep the 1.7-million-square-foot venue ready for Cardinals games, concerts, and major events

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) — As the 2026 NFL season gets underway, ABM (NYSE: ABM), a leading provider of facility, engineering, and infrastructure solutions, is highlighting a longstanding partnership that helps keep State Farm Stadium clean, welcoming, and ready for game days and other major events. Since 2022, more than 200 ABM professionals have supported janitorial services across the 1.7-million-square-foot venue, helping prepare the stadium for Cardinals games, concerts, and other high-profile events throughout the year.

Behind every Cardinals game, concert, and major event is an experienced onsite janitorial team supporting the thousands of fans and guests who pass through State Farm Stadium’s turnstiles. Drawing on ABM’s deep sports and entertainment experience, these professionals help meet the demands of one of the region’s busiest venues.

“Great fan experiences start long before the gates open, and our team understands the tremendous amount of work and attention to detail required behind the scenes,” said Valerie Burd, President of Business & Industry, ABM. “They know the important role they play in delivering a first-class experience for every fan, player, employee, and visitor. We’re excited to build on that foundation through our partnership with the Cardinals.”

Opened in 2006, State Farm Stadium is home to the Arizona Cardinals and has become one of the nation’s most recognizable sports and entertainment destinations. The 63,400-seat venue has hosted three Super Bowls, the NCAA Men’s Final Four, the annual Fiesta Bowl, and major concerts and events. Its retractable roof and innovative natural-grass field tray allow the stadium to transform for events of dramatically different scale and format.

“The best venue experiences feel effortless to the fan, but making them feel that way takes incredible coordination and strategy,” said Brian Grant, Vice President, Sports & Entertainment, ABM. “Our onsite team understands the rhythm of this building: what has to happen before an event, what it takes to perform when tens of thousands of people arrive, and how quickly the venue needs to be ready for whatever comes next. They take real pride in helping State Farm Stadium shine.”

The relationship also extends beyond the stadium through ABM’s support of Cardinals Climb Hike for Special Needs, an Arizona Cardinals Foundation initiative benefiting organizations that serve individuals with intellectual and developmental disabilities. The initiative reflects a shared commitment to making a positive impact not only on the experiences taking place inside the stadium, but throughout the Arizona community.

The Cardinals partnership further strengthens ABM’s presence in the Phoenix sports and entertainment market, where ABM teams support venues across professional football, baseball, and basketball. Nationwide, ABM serves many of the country’s leading stadiums, arenas, and entertainment destinations, providing scalable facility solutions designed to help create clean, safe and enjoyable environments for fans, teams, and staff.

For more information about ABM’s Sports & Entertainment solutions, visit www.abm.com/industries/sports-entertainment.

About ABM
ABM (NYSE: ABM) is one of the world’s largest providers of integrated facility, engineering, and infrastructure solutions. Every day, our over 100,000 team members deliver essential services that make spaces cleaner, safer, and efficient, enhancing the overall occupant experience.

ABM serves a wide range of market sectors including commercial real estate, aviation, education, mission critical, and manufacturing and distribution. With over $8 billion in annual revenue and a blue-chip client base, ABM delivers innovative technologies and sustainable solutions that enhance facilities and empower clients to achieve their goals. Committed to creating smarter, more connected spaces, ABM is investing in the future to meet evolving challenges and build a healthier, thriving world. ABM: Driving possibility, together.

For more information, visit www.ABM.com.

MEDIA CONTACT:
Michael Valentino
ABM
media@abm.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fa69b5ed-c710-451a-bf7e-f7c70276dcd8

New survey of 1,001 U.S. adults reveals how rising education costs, shifting ROI expectations, and growing student debt anxiety are reshaping how Americans plan and pay for higher education

ISELIN, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) — Provident Bank, a leading New Jersey-based financial institution, announced today the results of its 2026 Higher Education Survey, which examines how American families are navigating the rising cost of higher education, evolving views on the value of a degree, and growing interest in alternative education paths. The findings reflect a financial reassessment now evident in how families plan, save, and make decisions related to college.

The financial pressure surrounding higher education remains a significant concern. The survey found that nearly 70% of respondents are concerned about the cost of higher education, and more than 70% say rising costs have already prompted changes in their families’ plans. As families weigh their options, the data reflects a more nuanced picture of how Americans think about the value of education today. Only 20.6% believe the financial return of a degree is clearly worth the cost, and 30.4% identify trade or technical school as the path offering the best financial return available.

“Higher education can be a powerful investment in a person’s future, but how families plan and pay for it can have financial implications for years to come. As a trusted financial partner, we have a responsibility to help customers make informed decisions, understand the options available to them, and provide tailored solutions that support both their educational aspirations and their long-term financial goals,” said Anthony Labozzetta, President & CEO, Provident Bank.

Key data highlights include:

• The Financial Return of a Degree Is No Longer a Given: Only 20.6% of respondents believe a higher education degree is clearly worth the cost today. 48.5% say it depends on the school, degree, and career path, and 19.4% say the cost outweighs the potential return outright. Skepticism also extends to graduate school: 43.9% of respondents say the financial return on a master’s degree is weaker than it was 10 years ago, either somewhat weaker (22.2%) or much weaker (21.7%), while only 13.8% say it is much stronger.
• Rising Costs Are Driving Behavioral Changes: 71.3% of respondents say rising education costs have changed their or their family’s plans either significantly (28.4%) or somewhat (42.9%). Less than 28% say costs have had no effect on their planning. Nearly 70% are extremely or very concerned about the cost of higher education today.
• Trade School Is Gaining Ground as a Financial Decision: 30.4% of respondents identify trade school or technical school as the education path offering the best financial return today, second only to four-year college (35.4%). Nearly two in three respondents (65%) say concerns about student debt have made trade schools, technical schools, or certificate programs more appealing, with more than 30% finding them much more appealing. 61.7% say they are more likely now than a few years ago to consider lower-cost education options such as in-state universities, community colleges, or trade schools.
• Savings and Debt Planning Are Lagging Behind Rising Costs: 19.4% of respondents are unsure how much student loan debt they or their child will need to take on. Among those who do expect debt, 9.9% expect $100,000 or more, and 11.8% expect between $50,000 and $74,999. Only 7.9% started saving before their child was born, and 13.5% have not started and do not plan to.
• Banks Have a Clear and Growing Opportunity to Support Families: 51.4% of respondents say it is extremely or very important that their bank offers dedicated products or guidance for saving toward education. However, only 24.4% say their current bank offers this kind of guidance, and they actually use it. 18.4% say their bank offers nothing at all in this area. As families face one of the most consequential financial decisions of their lives, the data points to a meaningful and largely untapped role for financial institutions.

“Planning for higher education is one of the most complex financial challenges a family faces, and our survey shows that most feel they’re doing it without adequate support. Provident’s Financial Wellness Center is designed to address that. From 529 guidance to education savings tools that help families understand their options before the bills arrive, we’re here to help families plan smarter, not just save harder,” said Renee Altomonte, Executive Vice President, Retail Banking Director, Provident Bank.

The survey was conducted by Pollfish, a market research provider, on behalf of Provident Bank. The findings are based on responses from 1,001 U.S. adults currently paying or saving for higher education — either their own or a dependent’s — across all four census regions, spanning a range of income levels, employment statuses, and age groups.

About Provident Bank

Founded in Jersey City in 1839, Provident Bank is the oldest community-focused financial institution based in New Jersey and is the wholly owned subsidiary of Provident Financial Services, Inc. (NYSE: PFS). With assets of $25.66 billion as of June 30, 2026, Provident Bank offers a wide range of customized financial solutions for businesses and consumers with an exceptional customer experience delivered through its convenient network of 135 branches across New Jersey and parts of New York and Pennsylvania, via mobile and online banking, and from its customer contact center. The bank also provides fiduciary and wealth management services through its wholly owned subsidiary, Beacon Trust Company, and insurance services through its wholly owned subsidiary, Provident Protection Plus, Inc. To learn more about Provident Bank, go to www.provident.bank or call our customer contact center at 800.448.7768.

Media Contact:

Keith Buscio, First Vice President, Director of Public Relations
Keith.Buscio@provident.bank

• U.S. FDA has granted Fast Track designation for TX2100 in HHT and cleared the Investigational New Drug (IND) application for the TX2100 Phase 1b clinical trial in HHT patients in the U.S.
• TX2100 Phase 1a clinical trial topline results demonstrated single ascending doses of TX2100 were generally safe and well-tolerated in healthy adult volunteers
• Company plans to initiate an open-label TX2100 Phase 1b clinical trial in patients with hematologic-support dependent HHT by year-end 2026, and initiate a Phase 2 clinical trial in parallel in patients with moderate-to-severe HHT in early 2027

WATERTOWN, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced favorable topline results from its Phase 1a clinical trial evaluating TX2100, an investigational VHH-Fc fusion antagonist antibody targeting the APJ (apelin) receptor, in healthy adult volunteers. The clinical trial was designed to support the advancement of clinical development for TX2100 as a potential treatment for Hereditary Hemorrhagic Telangiectasia (HHT), a rare, inherited vascular disorder with no currently approved therapies. The Company also announced that the U.S. Food and Drug Administration (FDA) granted TX2100 Fast Track Designation for HHT. In addition, the FDA recently cleared the Company’s Investigational New Drug (IND) application to conduct the upcoming TX2100 Phase 1b clinical trial in the U.S. in patients with HHT.

“We are very excited about our TX2100 clinical program as a potential first-in-class, selective anti-angiogenic therapy for HHT, a disease with no approved treatments,” said Alise Reicin, M.D., President and Chief Executive Officer of Tectonic Therapeutic. “We are proceeding into clinical trials in HHT patients with a clear rationale: a differentiated mechanism, supportive preclinical data, and the favorable safety profile observed in the Phase 1a single ascending dose clinical trial. We look forward to evaluating TX2100 in patients living with HHT in our Phase 1b and Phase 2 trials, which are planned to advance in parallel in the months ahead.”

The TX2100 Phase 1a clinical trial met its primary objectives, including the following:

• Single ascending doses of TX2100, administered intravenously and subcutaneously, were generally safe and well-tolerated across all six planned dose cohorts.
• Treatment-emergent adverse events (TEAEs) were mild or moderate and transient. There were no deaths, serious adverse events (SAEs) or severe TEAEs at any dose. No clinically significant changes were observed in vital signs, laboratory assessments or electrocardiograms. Anti-drug antibody (ADA) results are pending.
• Pharmacokinetic (PK) results reflected target-mediated drug disposition (TMDD) at low concentrations, confirming TX2100’s high affinity binding to the APJ receptor and clearance through this mechanism, which is consistent with potent target engagement.
• Dose selection for the upcoming Phase 1b and Phase 2 clinical trials is being informed by two independent methods: exposures associated with high receptor occupancy inferred from the observed TMDD in the Phase 1a clinical trial, and target exposure levels shown to drive activity in nonclinical models of HHT. These two methods converged on a consistent target exposure range, supporting the approach to dose selection.
• The observed PK results support exploration of once weekly and every other week subcutaneous dosing regimens in future clinical trials.

Detailed results from the TX2100 Phase 1a clinical trial, including safety, tolerability, PK and ADA results will be presented at the CureHHT 16^th HHT International Scientific Conference, taking place October 12-16, 2026.

Marcella K. Ruddy, M.D., Chief Medical Officer of Tectonic Therapeutic commented, “Today’s topline safety results in healthy volunteers are consistent with TX2100’s preclinical results, including toxicology studies that demonstrated no dose limiting toxicities with wide safety margins. We selected our target exposures using two independent methods that pointed to the same range, which gives us confidence in our approach. Data from the ongoing Part B multiple-dose cohort of the Phase 1a trial will further confirm the dose-exposure relationship and dose selection for Phase 2.”

Tectonic plans to advance TX2100 into two clinical trials in HHT in the upcoming months: an open-label Phase 1b clinical trial in patients with hematologic-support dependent HHT, with endpoints exploring an improvement in need for iron and red blood cell support, as well as an improvement in hematologic parameters, and a placebo-controlled Phase 2 clinical trial in moderate-to-severe HHT patients, with endpoints expected to include epistaxis, hemoglobin, hematologic support, and other endpoints relevant to HHT. Phase 1b and Phase 2 trials are planned to run in parallel, with the Phase 1b anticipated to initiate by year-end 2026 and the Phase 2 trial anticipated to initiate in early 2027.

The clinical program for TX2100 has achieved recent regulatory milestones with the U.S. FDA. In August 2026, the FDA cleared the Company’s IND application for TX2100 for the treatment of HHT, enabling Tectonic to conduct the planned open label Phase 1b clinical trial in patients with HHT in the U.S. In September 2026, the FDA granted TX2100 Fast Track Designation for the treatment of HHT. Fast Track Designation is an FDA process designed to facilitate the development and expedite the review of investigational treatments intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs.

About the Phase 1a clinical trial with TX2100

The Phase 1a clinical trial is a randomized, double-blind, placebo-controlled, single ascending dose (SAD), first-in-human trial conducted at CMAX Clinical Research in Adelaide, South Australia (ANZCTR registration: ACTRN12626000242325). The trial enrolled 48 healthy adult volunteers (men and women of non-childbearing potential, ages 18–55) across six sequential dose cohorts of eight participants each, randomized 3:1 to receive a single dose of TX2100 or matching placebo, administered via intravenous (IV) infusion or subcutaneous (SC) injection: Cohort A, 0.1 mg/kg IV; Cohort B, 0.3 mg/kg IV; Cohort C, 100 mg SC; Cohort D, 1 mg/kg IV; Cohort E, 300 mg SC; Cohort F, 600 mg SC. The primary objectives of the trial were to characterize the safety and tolerability of TX2100, assessed by the incidence of adverse events (AEs) and serious adverse events (SAEs), and clinically significant changes in safety laboratory parameters, 12-lead ECGs, and vital signs. The key secondary objective was to characterize the pharmacokinetic profile of TX2100; immunogenicity was also assessed.

Following the completion of Part A of the TX2100 Phase 1a clinical trial, Tectonic is conducting Part B of the trial which is a multiple dose cohort and has completed enrollment. Part B is evaluating six healthy volunteers in an open-label design who will be dosed with 600 mg SC on Day 1, followed by 200 mg SC dose on Day 8 and 200 mg SC dose on Day 15.

About TX2100, a VHH-Fc fusion antagonist antibody
TX2100, is a VHH-Fc fusion antagonist antibody that binds to the APJ receptor (also known as the apelin receptor; APLNR), a GPCR that mediates signaling by the pro-angiogenic peptide hormone apelin. APJ represents a differentiated approach for the potential treatment of HHT. APJ is a selective anti-angiogenic target that is primarily expressed in endothelial cells and is generally quiescent under normal physiological conditions, but is upregulated during pathologic angiogenesis, including in HHT preclinical models. TX2100 is designed as a selective APJ antagonist intended to inhibit disease-associated angiogenic signaling with the goal of providing a more favorable safety profile compared to less selective anti-angiogenic approaches. Anti-angiogenic agents have demonstrated activity in HHT preclinical models and in patients, and APJ antagonism has shown activity in multiple HHT preclinical models, supporting development of TX2100 for this indication.

About Hereditary Hemorrhagic Telangiectasia (HHT)
HHT is a rare, inherited vascular disorder affecting an estimated 75,000 people in the United States. HHT is the second most common inherited bleeding disorder and a disease for which there are currently no approved therapies. It is characterized by fragile, abnormal blood vessels that lead to recurrent bleeding, which can reduce quality of life, result in emergency room visits and hospitalizations, as well as chronic anemia requiring frequent iron infusions and/or blood transfusions. Many patients with HHT also develop arteriovenous malformations (AVMs) in vital organs such as the lungs, brain, and liver that, if left untreated, are at risk of rupturing and can result in serious and potentially life-threatening complications including lung or brain hemorrhage, stroke, heart failure, or death. Despite being a rare disease and the second most common inherited bleeding disorder, there are currently no approved therapies.

About Tectonic
Tectonic Therapeutic is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Leveraging its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit https://tectonictx.com/ and follow us on LinkedIn.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are “forward-looking statements.” These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the potential of TX2100, including its potential future benefit to patients, the Company’s plan with respect to TX2100, including the design, objectives, initiation, timing, progress and results of current and future clinical trials of TX2100, including the ongoing Phase 1a clinical trial for TX2100 and the planned Phase 1b and Phase 2 clinical trials for TX2100; the Company’s expectations regarding the presentation of full clinical data from the Phase 1a clinical trial; and the Company’s business strategies, plans and prospects. These forward-looking statements are based on Tectonic’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Tectonic’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions and ongoing global conflicts, heightened inflation and uncertain credit and financial markets, on Tectonic’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; Tectonic’s ability to realize the benefits of its collaborations and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause Tectonic’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified under the heading “Risk Factors” in Tectonic’s quarterly report on Form 10-Q filed for the quarter ended June 30, 2026 and in other filings that Tectonic makes and will make with the SEC in the future. Tectonic expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

CONTACT: Contacts:
Investors:
Dan Ferry
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

Media:
Kathryn Morris
The Yates Network
kathryn@theyatesnetwork.com
(914) 204-6412

LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) — AXIL Brands, Inc. (“AXIL,” “we,” “us,” “our,” or the “Company”) (NYSE American: AXIL), an emerging global consumer products company for AXIL® hearing protection and enhancement products and Reviv3® hair and skin care products, today announced that the company expects to report its Fiscal First Quarter results for the period ending August 31, 2026 on Tuesday, October 6, after the close of the market.

Jeff Toghraie, CEO and Jeff Brown, CFO of Axil Brands will host a conference call (audio only) to discuss the results and provide a corporate update for investors at 5:00 PM ET, which will be accessible via telephone or over the internet. A question and answer (Q&A) session will be moderated at the conclusion of the prepared remarks.

Investors can access the live event by dialing in to 1-877-425-9470 or 1-201-389-0878 or by logging on for the webcast at https://viavid.webcasts.com/starthere.jsp?ei=1777813&tp_key=7330938b30

Investors wishing to ask questions are encouraged to send any questions in advance of the call (please submit by 12PM ET) to the following email address in advance:

Investors@goaxil.com

The call will be available via telephone replay through October 13, 2026. The telephone number for the replay is 1-844-512-2921 or 1-412-317-6671 and an access code, 13762995 will be required. A webcast (audiostream) will also be available for replay upon demand on the company’s corporate website, www.goaxil.com in the investor relations section.

About AXIL Brands, Inc.

AXIL Brands, Inc. is dedicated to developing and delivering innovative hearing enhancement and protection products that combine advanced technology with exceptional comfort and performance. The Company also operates in the hair and skin care market through its Reviv3 Procare brand. For more information, please visit goaxil.com.

Investor Relations:
investors@goaxil.com

Two new whitepapers argue that neither failure is about how smart the AI is, and that a bigger model fixes neither

SUNNYVALE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) — As thousands of AI builders and business leaders gather at The AI Conference in San Francisco, eGain Corporation (NASDAQ: EGAN) published two whitepapers on the two problems most likely to stop a corporate AI project, and argues both trace back to the same overlooked cause: companies never organized the information their AI depends on.

The first paper, Ending Runaway Token Costs in Enterprise AI, addresses a complaint moving from software teams into customer service and back-office operations: AI bills that grow faster than expected and are nearly impossible to forecast. Companies pay for AI by the unit of work it does, and eGain’s argument is that most of that work is wasted. Asked a simple question, the system reads through a sprawl of company documents from scratch, every single time, because no one ever organized that material or mapped how it fits together. eGain likens it to sending a new hire into an unlabeled warehouse to find one box, then sending them back in for the next box, and the next. A second source of waste is using AI to handle work that is really just a rule. Calculating a late fee or checking whether someone qualifies for a refund does not require judgment, and asking an AI to reason it out fresh each time is an expensive way to do arithmetic. eGain’s answer is to organize company knowledge into a single trusted, mapped source so the AI goes straight to what it needs, and to route routine decisions to ordinary software. The company is confident enough in the savings that it prices many contracts on results rather than usage, absorbing the risk of the bill itself.

The second paper, The Trust Gap in AI Self-Service, explains why so many customer-facing AI projects look impressive in a demo and stall before going live. When a human service rep uses AI, the rep catches the mistakes. When the customer talks to the AI directly, no one does. That makes the industry’s favorite scorecard misleading. A system that is 95% accurate is not defined by the 95%. It is defined by what the other 5% looks like. An AI that says “I’m not certain, let me get you a person” has failed safely. An AI that states the wrong thing about a customer’s mortgage, confidently, with the bank’s name on it, has not. The paper is also pointed about a popular technical shortcut: letting the AI decide in the moment which company system to reach into and what to do there. eGain argues that approach is not dependable enough for live customer use, because there is no expert standing by to notice that the wrong account was charged.

“A runaway AI bill almost never means the model is too small. It means nobody told it where to look,” said Ashu Roy, CEO of eGain. “And once a customer is talking to the AI directly, there is no one left to catch a mistake before it lands. Getting the underlying information right is not a feature. It is the whole job.”

Availability: Both whitepapers are at eGain.com/resources. Journalists and analysts at The AI Conference can request advance copies and executive briefings at press@egain.com.

About eGain
eGain is a leading provider of AI-powered knowledge management and customer experience automation solutions and was named a Leader in the Gartner inaugural Magic Quadrant for Customer Service Knowledge Management Systems. With over 25 years of experience in knowledge management, eGain helps enterprises unify siloed content, automate trusted knowledge workflows, and deliver measurable AI-ROI through proven frameworks and methods. Global 2000 companies across industries rely on eGain to transform customer service, improve employee productivity, reduce costs, and accelerate AI adoption. Visit www.eGain.com for more info.

Gartner Disclaimer
Gartner, Magic Quadrant for Customer Service Knowledge Management Systems, Pri Rathnayake, Jennifer MacIntosh, Patrick Quinlan, Drew Kraus, 16 July 2026.

Media Contact
eGain Media Relations
press@egain.com

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Lucas Donigian as Senior Vice President, Business Development, effective September 28, 2026. Mr. Donigian brings more than 20 years of biotechnology industry experience, with a background in business development, corporate strategy, and alliance management. He has a demonstrated history of executing high-value oncology partnerships, including in the ADC space, with an aggregate deal value of over $2 billion.

“We are thrilled to welcome Lucas to the Sutro team at a time of significant momentum across our pipeline, as we build on our encouraging early clinical data with STRO-004, advance STRO-006 in the clinic, and progress STRO-227, our first wholly-owned dual-payload ADC, toward IND submission this year,” said Jane Chung, Sutro’s Chief Executive Officer. “Business development has always been a core pillar of Sutro’s strategy, and Lucas has a deep history of creating high-value partnerships from differentiated platform technologies at leading oncology companies. His experience will be instrumental in building shareholder value as we continue seeking opportunities to progress our next-generation ADC platform through strategic collaborations that complement our proprietary pipeline strategy.”

“The combination of the encouraging clinical profile of STRO-004 to date, expected data from STRO-006 and STRO-227 next year, and our novel ADC design capabilities provides near-term validation of Sutro’s unique ADC platform and represents substantial partnership opportunities,” said Mr. Donigian. “I am excited to join the team and look forward to building on Sutro’s existing collaborations and establishing new partnerships that can extend the reach of these optimally designed medicines to more patients.”

Mr. Donigian most recently served as Vice President, Head of Business Development & Licensing and Commercial at Zymeworks Inc., where he led the end-to-end execution of Zymework’s licensing agreement with Jazz Pharmaceuticals for zanidatamab. Prior to Zymeworks, Mr. Donigian was Director, Business Development and BioPharma Collaboration at NanoString Technologies, where he led the company’s Companion Diagnostic partnering efforts, executing high-value partnerships with several leading pharmaceutical companies as well as the divestiture of the nCounter diagnostics business to Veracyte. Earlier in his career, Mr. Donigian worked as a Senior Research Associate in Cancer Biology at OncoMed Pharmaceuticals. He holds an MBA from the Michael G. Foster School of Business, University of Washington, and a BS in Molecular Biology from San Jose State University.

Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

In connection with Mr. Donigian’s appointment as Senior Vice President, Business Development, effective October 15, 2026, the Compensation Committee of Sutro’s Board of Directors granted Mr. Donigian stock options to purchase 25,000 shares of Sutro common stock and 1,750 restricted stock units (RSUs). The grants were made as an inducement material to Mr. Donigian’s acceptance of employment with Sutro and were approved by the Compensation Committee of Sutro’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options and RSUs are subject to the terms and conditions of Sutro’s Amended and Restated 2021 Equity Inducement Plan. One-fourth of the total number of shares underlying the stock options will vest on the one-year anniversary of Mr. Donigian’s hire date and monthly thereafter until fully vested on the fourth anniversary, subject to Mr. Donigian’s continued service with Sutro on each such vesting date. One-fourth of the total number of shares subject to the RSUs will vest on the one-year anniversary of the grant date and annually thereafter until fully vested on the fourth anniversary, subject to Mr. Donigian’s continued service with Sutro on each such vesting date.

About Sutro Biopharma

Sutro Biopharma, Inc. is a clinical-stage biotechnology company advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.

For more information, follow Sutro on social media @Sutrobio or visit www.sutrobio.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated preclinical and clinical development activities; timing of announcements of IND submissions, trial initiation, clinical results, and other regulatory filings; outcome of discussions with regulatory authorities; potential benefits, efficacy and safety profile of the Company’s product candidates and platform; potential business development and partnering transactions; potential market opportunities for the Company’s product candidates; the positioning of the Company’s product candidates in the competitive landscape; the timing and receipt of anticipated future milestone and royalty payments; and the Company’s expected cash runway. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the Company’s ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, the market size for the Company’s product candidates to be smaller than anticipated, clinical trial sites, supply chain and manufacturing facilities, the Company’s ability to obtain, maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, the Company’s ability to fund development activities and achieve development goals, the Company’s ability to protect intellectual property, the Company’s commercial collaborations with third parties, the impact of health pandemics, tariffs, regional geopolitical conflicts, changes in interest rates, inflation, potential uncertainty with respect to the debt ceiling and government shutdowns, and other risks and uncertainties described under the heading “Risk Factors” in documents the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Investor Contact
Emily White
Sutro Biopharma
(650) 823-7681
ewhite@sutrobio.com

Media Contact
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com

Incidence and prevalence of OPSCC continue to rise in the U.S. largely driven by HPV infection

OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L+ setting in the U.S. with approximately 14,000 patients eligible for treatment annually

NORWOOD, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that the first patient has been dosed in its TEMPO-1 registrational study of CRB-701, a next-generation Nectin-4 targeted antibody drug conjugate (ADC), in second-line and beyond (2L+) oropharyngeal squamous cell carcinoma (OPSCC).

“For patients with recurrent or metastatic head and neck cancer, there remains a significant unmet need for new treatment options after progression on frontline therapy,” said Dr. Cesar A. Perez, Director of the Drug Development Unit at Sarah Cannon Research Institute at Florida Cancer Specialists & Research Institute in Orlando, FL, and Principal Investigator of the TEMPO-1 study. “The current standard options have been largely unchanged since the introduction of PD-1 inhibitors nearly a decade ago. We are proud that SCRI at Florida Cancer Specialists & Research Institute is helping evaluate a potential new therapeutic approach through the TEMPO-1 study.”

HPV infection is driving the rise of both the incidence and prevalence of OPSCC in the U.S. The disease primarily affects men in their 50s and 60s who have little or no history of smoking or heavy alcohol use. Each year approximately 14,000 OPSCC patients are estimated to be eligible for 2L treatment, and approximately 7,000 patients are estimated to die from the disease in the U.S. alone.

“Dosing the first patient in our TEMPO-1 trial marks an important step in advancing CRB-701 as a potentially novel targeted therapeutic for those impacted by OPSCC,” said Leonardo Nicacio, M.D., Chief Medical Officer of Corbus Pharmaceuticals. “Based on the Phase 1/2 data we presented at ASCO 2026, we believe that CRB-701 has the potential to deliver meaningful clinical benefit with a manageable safety profile in this underserved patient population. We are excited to be underway with TEMPO-1, which is designed to generate the evidence needed to support a potential regulatory submission.”

Study Design

TEMPO-1 is a randomized controlled study (n=250) designed to evaluate the efficacy and safety of CRB-701 compared with investigator’s choice of capecitabine, cetuximab or docetaxel. The study’s primary endpoint is objective response rate (ORR), which is intended to support a potential accelerated approval; overall survival (OS) is intended to support potential conversion to full approval.

FDA approval for the TEMPO-1 study to proceed was supported by results from Corbus’ ongoing Phase 1/2 clinical study of CRB-701, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. In an analysis of patients with 2L+ OPSCC treated at the 3.6 mg/kg dose, CRB-701 achieved a confirmed ORR of 42.9%, with a median duration of response (DoR) of 6.3 months and a median progression-free survival (PFS) of 5.6 months (ongoing).

About CRB-701

CRB-701 (SYS6002) is a next-generation antibody drug conjugate targeting Nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using monomethyl auristatin E (MMAE) as the payload. Nectin-4 is a clinically validated, tumor-associated antigen in urothelial cancer and highly expressed in other tumor types such as cervical and head and neck squamous cell carcinoma (HNSCC). The FDA has granted two Fast Track designations to CRB-701 in HNSCC and cervical cancer.

About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act of 1995, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, anticipated timing for initiation of clinical trials, anticipated regulatory interactions and outcomes, including alignment with FDA on trial design, potential accelerated approval, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities, sufficiency of cash runway  and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. There can be no assurance that TEMPO-1 will achieve its primary or secondary endpoints, that CRB-701 will receive accelerated or full approval from the FDA, or that previously reported clinical data will be replicated in larger controlled studies.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission including those described in our Annual Report on Form 10-K for the year ended December 31, 2025, and other filings we make with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.

INVESTOR CONTACTS:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

MEDIA CONTACT:
Liz Melone
Founder & Principal
Melone Communications, LLC
liz@melonecomm.com

Launch brings single sign-on, user provisioning, and every Asure solution together in one platform for resellers serving more than 85,000 employers and 1.5 million employees

AUSTIN, Texas, Sept. 29, 2026 (GLOBE NEWSWIRE) — Asure Software, Inc. (Nasdaq: ASUR), a provider of payroll and HR solutions for employers and enterprise payroll tax and treasury infrastructure, launched AsureCentral to its reseller network at its annual reseller training event last week and took its first resellers live on the platform. AsureCentral is the platform where all of Asure’s solutions come together. It combines single sign-on, user provisioning, and role-based access with payroll, tax, HR, recruiting, time and attendance, benefits, and Luna AI in one environment for resellers and the employers they serve.

Until now, AsureCentral was available only to Asure’s approximately 30,000 direct-employer clients, representing more than 300,000 employees. Asure’s resellers serve more than 85,000 employer clients representing more than 1.5 million employees. Opening AsureCentral to that network substantially expands the addressable market for the platform and for Asure’s recruiting, time and attendance, and benefits solutions, where separate logins had added friction to adoption alongside payroll. Additional resellers will move onto the platform following the launch.

“Our reseller network reaches nearly three times as many employers and five times as many employees as our direct business, but separate application experiences made it harder to bring the full breadth of Asure to those clients,” said Pat Goepel, Chairman and CEO of Asure. “AsureCentral is not just a single sign-on. It’s how a reseller sets up users, manages access, and delivers payroll, HR, time, recruiting, benefits, and AI to every client from one platform. Every Asure solution lives there, so each reseller we bring onto AsureCentral extends the reach of everything we build.”

For resellers, AsureCentral provides one place to provision and manage users across every Asure solution their clients use, for every client they serve, with role-based security and multi-factor authentication protecting sensitive payroll and HR data. Resellers can white-label the experience with their own logo in the platform header. Inside each client, employers, managers, and employees get a view built around their role: employees manage their own pay and HR records, managers handle approvals such as time off and timecards, and administrators see across payroll, HR, time, and recruiting. For resellers that use multiple providers today, having Asure’s full range of solutions in one platform gives them a practical reason to consolidate client relationships on Asure.

Luna AI is embedded in AsureCentral to help employers, managers, and employees get answers and complete payroll and HR tasks within their workflows. Employees can get help with pay and HR questions, while managers and administrators can see items that need attention, including exceptions and approvals.

About Asure Software

Asure (Nasdaq: ASUR) provides payroll and HR solutions for employers and enterprise payroll tax and treasury infrastructure for large organizations. For employers, Asure’s platform covers payroll, HR, recruiting, time and attendance, benefits, and compliance — delivered through AsureCentral, its connected platform, or through AsureWorks, its managed services offering for employers who prefer to outsource the work entirely. For large enterprises, Asure’s payroll tax and treasury infrastructure handles multi-jurisdiction tax filing, funding, and money movement, integrating with platforms including Workday, Oracle, and SAP. For more information, visit www.asuresoftware.com.

Investor Relations Contact

Patrick McKillop
Vice President, Investor Relations
Asure
617-335-5058
patrick.mckillop@asuresoftware.com

ANDOVER, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) — Byrna Technologies Inc. (“Byrna” or the “Company”) (Nasdaq: BYRN), a personal defense technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions, today announced a new marketing partnership with iHeartMedia’s “The Bobby Bones Show” – America’s #1 country morning show, which reaches millions of listeners across more than 180 station nationwide. The recently launched campaign is designed to introduce Byrna’s less-lethal personal security solutions to a broad audience through one of the nation’s most popular country radio programs.

The Bobby Bones Show spans country music, entertainment, family, lifestyle, and pop culture, providing Byrna an opportunity to connect with a large and loyal listener base through a practical message centered on personal safety, preparedness, and protection.

“Partnering with ‘The Bobby Bones Show’ aligns with our efforts to make personal safety more relatable and accessible to a broader mainstream audience,” said Byrna CEO Conn Davis. “The show has built a trusted connection with millions of listeners nationwide, making it an ideal partner as we continue to evolve our brand and expand awareness of Byrna’s less-lethal personal security solutions. This partnership also reflects our continued effort to reallocate existing media investments toward trusted platforms with larger mainstream audiences. We believe that this change is directly aligned with our strategy to drive greater brand awareness while maintaining a disciplined approach to marketing.”

The campaign includes national radio endorsements, podcast integrations, and digital media placements designed to increase brand awareness, improve customer education, and drive engagement with prospective customers.

The partnership represents another step in Byrna’s broader marketing evolution as the Company continues to expand awareness of its less-lethal personal security solutions among mainstream consumers. As part of this effort, Byrna is refining its messaging around everyday personal safety, preparedness, and protection while reallocating advertising spend within its existing iHeartMedia portfolio toward programming with broader mainstream reach.

About Byrna Technologies Inc.
Byrna is a personal defense technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions. For more information on the Company, please visit the corporate website here or the Company’s investor relations site here. The Company is the manufacturer of the Byrna^® CL, Byrna^® LE and Byrna^® SD personal security devices, state-of-the-art handheld CO2 powered launchers designed to provide a less-lethal alternative to a firearm for the consumer, private security, and law enforcement markets. To purchase Byrna products, visit the Company’s e-commerce store.

Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of the federal securities laws. All statements contained in this news release, other than statements of current and historical fact, are forward-looking statements. Often, but not always, forward-looking statements can be identified by the general use of words such as “plans,” “expects,” “intends,” “anticipates,” and “believes” and statements that certain actions, events or results “may,” “could,” “would,” “should,” “might,” “occur,” or “be achieved,” or “will be taken.” Forward-looking statements in this news release include but are not limited to our statements related to: the expected launch, timing, and scope of Byrna’s media partnerships through iHeartMedia; the anticipated audience reach and engagement of those campaigns across radio, podcast, digital, and other channels; the expected ability of these partnerships to introduce Byrna’s products and brand message to new and broader consumer audiences, including audiences who may not have historically considered personal security products; the anticipated impact of these partnerships on customer education, brand awareness, customer acquisition efficiency, and conversion across Byrna.com and the Company’s retail footprint; the Company’s broader marketing strategy and media investment approach, including the refinement of its messaging, the allocation of marketing resources, and the integration of digital and media channels; the anticipated introduction of dedicated campaign landing pages and promotional offers in connection with the partnerships; the Company’s plans to broaden the conversation around personal safety and reach a wider set of customer segments; and Byrna’s expectation that the partnerships will complement and support its broader marketing, retail expansion, and growth initiatives. Forward-looking statements are not, and cannot be, a guarantee of future results or events. Forward-looking statements are based on, among other things, opinions, assumptions, estimates, and analyses that, while considered reasonable by the Company at the date the forward-looking information is provided, inherently are subject to significant risks, uncertainties, contingencies, and other factors that may cause actual results and events to be materially different from those expressed or implied.

Any number of risk factors could affect our actual results and cause them to differ materially from those expressed or implied by the forward-looking statements in this news release, including, but not limited to: the risk that the campaigns do not launch on the anticipated timeline, are reduced in scope, or are not executed as planned; the risk that the partnerships do not achieve the anticipated audience reach, engagement, brand awareness, customer acquisition, or conversion results; the risk that increases in marketing expenditure in connection with these partnerships do not yield expected revenue increases or returns on investment; the risk of reputational harm or negative publicity arising from association with third-party personalities, media platforms, or partner programming, or from changes in the public profile, conduct, or commentary of such personalities; the risk that media partners, broadcasters, or advertising platforms determine to limit, modify, or terminate the placement or distribution of Byrna’s advertising; the loss of marketing partners; determinations by advertisers, social media platforms, or other media channels, or legislation or regulatory action, that prevents or limits marketing of some or all Byrna products; changes in consumer or political sentiment affecting product demand or the less-lethal personal defense category; the risk that efforts to broaden brand messaging or expand into new customer segments do not achieve anticipated market penetration or revenue results; disappointing market responses to current or future products or services; litigation, enforcement proceedings, or other regulatory or legal developments, including those relating to advertising, endorsements, or consumer protection; the risk that investments in e-commerce enhancements or digital capabilities, including dedicated campaign landing pages and improvements to Byrna.com, do not yield anticipated improvements in conversion rates, customer acquisition, or revenue; and general economic, competitive, and market conditions affecting consumer demand for personal defense products. The order in which these factors appear should not be construed to indicate their relative importance or priority. We caution that these factors may not be exhaustive; accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. Investors should carefully consider these and other relevant factors, including those risk factors in Part I, Item 1A, (“Risk Factors”) in the Company’s most recent Form 10-K and in subsequent Quarterly Reports on Form 10-Q, and should understand it is impossible to predict or identify all such factors or risks, and should not consider the foregoing list, or the risks identified in the Company’s SEC filings, to be a complete discussion of all potential risks or uncertainties, and should not place undue reliance on forward-looking information.

The Company assumes no obligation to update or revise any forward-looking information, except as required by applicable law.

Investor Contact:
Tom Colton and Greg Bradbury
Gateway Group, Inc.
949-574-3860
BYRN@gateway-grp.com

IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) — Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its third quarter 2026 financial results after the financial markets close on Tuesday, October 27, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s third quarter 2026 performance.

The link to the webcast will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com, and will be archived there for future replay. To access the live call by phone, please use the following link, which will provide you with dial-in details and a personal pin: https://register-conf.media-server.com/register/BIb765a5e68b554419b9df996402991220

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. Beta Bionics’ proprietary insulin dosing algorithm is the first FDA-cleared algorithm that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.

Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com

Media and Public Relations:
Felicia Sanborn
Vice President of Marketing
media@betabionics.com

Source: Beta Bionics, Inc.